Follow
Engineering T cells
Engineering T cells is a broad description of techniques used to modify a T cells obtained from a patient or healthy donor. T cells are a subset of immune cells responsible for targeting and killing tumor cells. Once harvested from a patient or donor, the T cells can be engineered in a laboratory making them better capable of killing a specific tumor. Examples of adoptive cell therapies using engineered T cells are T cell receptor (TCR)-engineered T cells and chimeric antigen receptor (CAR) T cells.
JUL 26, 2023 | 3:10 PM
Cell-based immunotherapy has become the new-generation cancer medicine, and “off-the-shelf” cell products that can be manufactured at large scale and distributed readily to treat...
JUL 26, 2023 | 11:20 AM
Chimeric antigen receptor (CAR)-reprogrammed immune cells offer exciting therapeutic potential for addressing oncology, autoimmune diseases, transplant medicine, and infections. However, cur...
MAY 16, 2023 | 8:00 AM
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
MAR 30, 2023 | 5:00 PM
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...
FEB 22, 2023 | 9:00 AM
Date: February 22, 2023 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Circular plasmid DNA has traditionally been used as a stable and efficient vector for gene expression and HDR-mediated...
FEB 22, 2023 | 5:30 AM
Many current technologies used in drug discovery and preclinical development programmes typically involve multi-step operations, extensive hands-on time, and lengthy liquid handling processe...
FEB 15, 2023 | 7:00 AM
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
DEC 07, 2022 | 9:00 AM
Date: December 07, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Join us for an exciting live panel webinar, as we celebrate the 60th anniversary of Gibco Cell Culture. The panelists...
NOV 16, 2022 | 9:00 AM
Date: November 16, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Cell therapy offers a new treatment option for a wide variety of diseases. Most cell therapies involve injecting a spe...
NOV 09, 2022 | 8:00 AM
Date: November 09, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is...
NOV 02, 2022 | 6:00 AM
The CRISPR revolution has begun and shows no signs of slowing down. CRISPR-Cas nuclease-based genome editing strategies hold great promise for the treatment of genetic disorders. However, a...
OCT 12, 2022 | 8:30 PM
Date: October 12, 2022, October 13, 2022 Time: 8:30pm (PDT), 11:30pm (EDT), 5:30am (CEST) High dimensional full spectrum flow cytometry holds the promise of addressing long-held questions in...
OCT 05, 2022 | 9:00 PM
Date: October 6, 2022 Time: Time: 9:30am IST, 12:00pm SGT, 1:00pm JST, KThe discovery of the CRISPR/Cas9 system has transformed research and now allows straightforward alterations in the geno...
OCT 05, 2022 | 9:00 AM
Learning Objectives 1. Identify 3 obstacles that inhibit the immune cell response to cancer. 2. List 3 aspects of T cells antitumor function that can be improved with costimulatory signals....
OCT 05, 2022 | 6:00 AM
The ultimate promise of tumor immunotherapy is dependent on the generation of effective immunity against cancer, including CD4 and CD8 T cell responses. However, activating T cells in cancer...
OCT 04, 2022 | 6:00 AM
The majority of disease-associated genetic variants are thought to have regulatory effects, including disruption of transcription factor (TF) binding and alteration of downstream gene expres...